Text Size
Santen Corporate (EN)

2025 IR News

RSS

IR News

Santen Launches Verkazia® (Ciclosporin Eye Drops (III) ) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults
Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List
Santen and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases
On December 1, Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
Santen Announces Cancellation of Treasury Shares
Santen Announces Completion of Share Buyback
Summary of Consolidated Financial Results for the Six Months Ended September 30, 2025 (IFRS)
Santen Announces Status of Share Buyback
Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Santen Launches SETANEO® Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension
Santen Korea Signs an Exclusive Promotion and Distribution Agreement for VEGF Inhibitors Beovu® and Lucentis® in the Republic of Korea
Announcement Regarding the Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Santen Announces Status of Share Buyback
Santen and RemeGen Announce Biologic License Application (BLA) Acceptance for RC28-E Intravitreal Injection in Diabetic Macular Edema in China
Santen Publishes its Annual Integrated Report “Santen Report 2025”
(Cancellation of Disclosure) Notice of suspension of the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration
Notice of Corporate Officer Changes
Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan
Santen Announces Status of Share Buyback
Santen Launches TAPCOM® in China for Patients with Open-Angle Glaucoma or Ocular Hypertension
Santen Obtains Manufacturing and Marketing Approval in Japan for SETANEO® 0.002% Ophthalmic Solution, a Bicyclic Prostaglandin Derivative that Acts on FP and EP3 Receptors, for Treatment of Glaucoma and Ocular Hypertension
Santen Announces New Licensing Agreement with RemeGen for RC28-E Intravitreal Injection, an Anti-VEGF/FGF Dual-Target Fusion Protein
Summary of Consolidated Financial Results for the Three Months Ended June 30, 2025 (IFRS)
Santen Announces Status of Share Buyback
Santen Applies for Manufacturing and Marketing Approval in Japan for STN1013900 (netarsudil mesylate), Treatment for Glaucoma and Ocular Hypertension
Santen Launches Ryjunea® in Germany for the Treatment of Pediatric Myopia
Corporate Governance Report
Santen Announces Status of Share Buyback
European Commission Approves Santen’s Ryjunea® to Slow Progression of Paediatric Myopia
Santen Announces Status of Share Buyback
Santen Announces FY2025-2029 Medium-Term Management Plan
Santen and Bayer Yakuhin Launch New Pre-Filled Syringe for EYLEA® 8 mg, EYLEA® 8 mg intraocular injection kit 114.3 mg/mL
Santen Announces Reversal of General Reserve
Santen Announces Share Buyback
Summary of Consolidated Financial Results for the Year Ended March 31, 2025 (IFRS)
Notice of Board of Director and Corporate Auditor Nominations
Santen Announces China NMPA Approval of Tapcom🄬 in Patients with Open-Angle Glaucoma or Ocular Hypertension
Santen Receives Positive CHMP Opinion in Europe for Ryjunea🄬 for slowing the progression of paediatric myopia
Santen Receives Excellence Award at NIKKEI Integrated Report Award 2024
Santen launches RYJUSEA🄬 Mini ophthalmic solution 0.025% Japan’s first ophthalmic solution for slowing myopia progression
Santen launches Rocklatan🄬 ophthalmic solution (netarsudil 0.02% and latanoprost 0.005%), in Singapore for the treatment of patients with open-angle glaucoma or ocular hypertension
Notice of Corporate Officer Changes
Revision of Dividend Forecast
Santen Announces Cancellation of Treasury Shares
Santen Reports the 3rd Quarter Fiscal 2024 Consolidated Performance
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved